Chromocell Therapeutics Total Liabilities

Chromocell Therapeutics (CHRO) currently reports a total liabilities of $140M as of June 2026. That compares with $7.3M in the prior-year period — up 1797.7% year over year. Use the charts on this page to explore Chromocell Therapeutics's total liabilities history and peer comparisons.

Chromocell Therapeutics's total liabilities increased from $7.3M to $140M — a 1797.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromocell Therapeutics reported $140M in total liabilities as of June 2026. That compares with $7.3M in the prior-year period — up 1797.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.